OR=9.3 for adults with DScores of 2–3 and 4–6 [compared with DS 0–1], respectively). Odds of CS (vs FS) were also higher with higher DScores (OR=6.9 and OR=7.6 for adults with a DS of 2–3 and 4–6 [compared with DS 0–1], respectively).

Conclusion Smoking is highly prevalent in patients with pCCLE. DScores were positively associated with CS and inversely associated with FS. Smoking cessation is particularly important for adults with pCCLE, and such efforts should target individuals from the most disadvantaged sociodemographic groups.

Acknowledgements The GOAL Cohort is supported by the Centers for Disease Control and Prevention (CDC) Grant 1U01DP005119. The content of this research is solely the responsibility of the authors and does not necessarily represent the official views of the CDC. The authors have no conflicts of interest to declare.

P58

SYSTEMIC LUPUS ERYTHEMATOSUS IN NATIVE SUB-SAHARAN AFRICANS: A SYSTEMATIC REVIEW AND META-ANALYSIS

¹Mickael Essouma, ¹Jan René Nkeke, ²Francky Teddy A Endomba, ^{3,4}Jean Joel Bigna, ^{1,5}Madeleine Singwe-Ngandeu, ⁶Eric Hachulla. ¹Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon; ²University of Bourgogne, Dijon, France; ³Centre Pasteur of Cameroon, Yaoundé, Cameroon; ⁴Faculty of Medicine, University of Paris Sud XI, Le Kremlin-Bicêtre, France; ⁵Yaoundé Central Hospital, Yaoundé, Cameroon; ⁶Claude Huriez Hospital, Lille University, Lille, France

10.1136/lupus-2020-eurolupus.105

Background This systematic review of literature and meta-analysis aimed to determine the prevalence, phenotype and treatment of systemic lupus erythematosus (SLE) in Native sub-Saharan Africans.

Methods PubMed, EMBASE, Web of Science, African Journals Online, and Global Index Medicus as well as references of retrieved papers were searched to select studies addressing SLE in Native sub-Saharan Africans and published during January 1, 2008– October 7, 2018. Results were pooled through narrative review and random-effects model. Heterogeneity (I^2) was assessed via the χ^2 test. Pooled estimates are expressed

with 95% confidence intervals. This study is registered with PROSPERO: registration number CRD42019139226.

Results Fifteen hospital-based studies were included out of 1502 records. The pooled prevalence of SLE was 1.7% (0.8–2.9). The mean age at diagnosis ranged from 28.8 to 39.2 years. The female proportion was 88%–100%. Rheumatological (5.1%–99.9%), dermatological (4.3%–100%) and hematological (1.4–86.9%) manifestations were the commonest. Patients had a high seroprevalence for anti-ribonucleoprotein 57.9% (36.4–77.9), anti-Smith 53.5% (40.4–66.2), anti-Sjogren syndrome antigen A 45.6% (19.2–73.4) and anti-Sjogren syndrome antigen B 33.7% (13.6–57.6) autoantibodies. The most used treatments were corticosteroids 99% (94.9–100) and antimalarials 62.8% (23.3–94.1). The pooled mortality rate was 10.3% (3.3–20.6); mainly due to infections, kidney and neurological involvement.

Conclusions Over the last 30 years, SLE was not rare among Native sub-Saharan Africans and its featured characteristics were earlier onset, female predominance, and high seropositivity for extractable nuclear antigen autoantibodies. The standard treatments were corticosteroids and antimalarials. The mortality rate was high. Population prevalence and incidence as well as full description of SLE characteristics in Native sub-Saharan Africans are needed.

P59

PREDICTORS OF RENAL SURVIVAL IN A COHORT OF PATIENTS WITH LUPUS NEPHRITIS WITH MORE THAN 30 YEARS OF FOLLOW-UP

¹Filipa Farinha, ²Ruth J Pepper, ³Daniel G Oliveira, ¹Thomas McDonnell, ¹David A Isenberg, ¹Anisur Rahman. ¹Centre for Rheumatology, University College London, London; ²Centre for Nephrology, University College London-Royal Free Campus, London, UK; ³Internal Medicine Dept., Centro Hospitalar e Universitário do Porto, Porto, Portugal

10.1136/lupus-2020-eurolupus.106

Background Despite the improvement in survival of patients with lupus nephritis (LN) over the last decades, LN is associated with progression to end-stage renal disease (ESRD) in a significant proportion of patients. We aimed to investigate the factors influencing renal survival in patients with LN.

Abstract P59 Figure 1 Kaplan-meier curves showing cumulative renal survival for patients with LN

Abstract P59 Table 1 Hazard ratio (HR) for possible predictors of ESRD, when the variables were analysed in pairs with COX regression analysis

COX Regression	HR [95%CI]	p
uPCR $\geq$ 42 at 12M	6.365 [1.431-28.321]	0.015
eGFR $\leq$ 76 at 12M	8.041 [2.831-22.834]	<0.001
uPCR $\geq$ 42 at 12M	8.027 [1.820-35.401]	0.006
Ethnicity (AC)	1.200 [0.361-3.989]	0.766
eGFR $\leq$ 76 at 12M	6.800 [2.490-18.572]	<0.001
Ethnicity (AC)	4.138 [1.235-13.870]	0.021
uPCR $\geq$ 42 at 12M	9.229 [2.104-40.481]	0.003
Histological class (III or IV)	286141.61 [<0.001 -7.149E+187]	0.953
eGFR $\leq$ 76 at 12M	4.300 [1.633-11.321]	0.003
Histological class (III or IV)	233853.34 [<0.001 -1.219E+192]	0.955
uPCR $\geq$ 42 at 12M	5.204 [1.169-23.163]	0.030
eGFR $\leq$ 82 at LN diagnosis	4.660 [1.476-14.713]	0.009
uPCR $\geq$ 42 at 12M	5.489 [1.226-24.574]	0.026
uPCR $\geq$ 262 at LN diagnosis	2.739 [0.939-7.992]	0.065
eGFR $\leq$ 76 at 12M	4.030 [1.548-10.495]	0.004
uPCR $\geq$ 262 at LN diagnosis	2.195 [0.826-5.836]	0.115
uPCR $\geq$ 42 at 12M	7.119 [1.615-31.385]	0.010
No antimalarials	3.828 [1.360-10.778]	0.011
eGFR $\leq$ 76 at 12M	3.659 [1.337-10.011]	0.012
No antimalarials	2.382 [0.857-6.621]	0.096
uPCR $\geq$ 42 at 12M	5.051 [1.097-23.349]	0.038
% Diastolic BP $>$ 80mmHg	1.010 [0.0990-1.030]	0.347
eGFR $\leq$ 76 at 12M	3.554 [1.214-10.407]	0.021
% Diastolic BP $>$ 80mmHg	1.012 [0.992-1.032]	0.239

uPCR: urinary protein-creatinine ratio, mg/mmol; eGFR: estimated glomerular filtration rate, mL/min/1.73m²; BP: blood pressure

Methods Single-centre retrospective observational study. Patients with biopsy-proven proliferative, membranous or mixed LN were included. Individual clinical files were reviewed to obtain demographic, clinical, laboratory and pathological data. Cox regression analysis was performed to investigate predictors of progression to ESRD and Kaplan-Meier curves were obtained.

Results We studied 187 LN patients (135 proliferative, 38 membranous and 14 mixed LN), followed for up to 42 years (mean 13 $\pm$ 9 years). Cumulative renal survival rates at 5, 10, 15 and 20 years were 93%, 85%, 78% and 70%, respectively. In univariable analysis, urinary protein/creatinine ratio (uPCR) above 42 mg/mmol or estimated glomerular filtration rate (eGFR) below 76 mL/min/1.73 m², one year after the diagnosis of LN, were the strongest predictors of progression to ESRD (figure 1), with hazard ratios (HR) of 8.081 [95%

CI:1.856–35.179] and 4.985 [95%CI:1.964–12.651], respectively. HR for uPCR and eGFR at the time of diagnosis were considerably smaller (2.508 [95%CI:1.062–5.922] and 2.833 [95%CI:1.156–6.945] respectively). Other factors associated with increased risk of ESRD were Afro-Caribbean ethnicity (HR=3.861 [95%CI:1.817–8.206]), proliferative LN (HR=3.423 [95%CI:1.049–11.173]), not having taken antimalarials (HR=2.180 [95%CI:1.089–4.363]) and poorly controlled diastolic blood pressure (HR=1.016 [95%CI:1.001–1.030]). The effect of uPCR and eGFR at one year remained significant after adjusting for ethnicity, histological class, uPCR and eGFR at the time of diagnosis, use of antimalarials and diastolic blood pressure (table 1).

Conclusions uPCR above 42 mg/mmol and eGFR below 76 mL/min/1.73 m², one year after the diagnosis of LN, were the strongest predictors of progression to ESRD.